Articles On Adherium (ASX:ADR)

Adherium (ADR) enters into a trading halt pending a capital raise announcementThe company is planning to launch a placement to sophisticated and professional investors but did not give details on to how much it was looking to raise Trading...

The ASX 200 falls 2.6%  after Wall St rout  Small caps recover manfully to be just 1% lower  AQC is turning out be a hell of a ride   Firstly, the Benchmark ASX 200 is down about 2.5% on Wednesday. It’s a fair whack, but hardly worse tha...

Respiratory medical devices business Adherium was out with a steeply discounted $13.5 million placement on Thursday morning to spend on product development, marketing and the like.

The ASX will open higher on Friday Fed’s Powell warns of more rate hikes ECB makes a historic 75bp rate increase Local shares are set to open higher today. At 8am AEST, the ASX 200 September futures contract is pointing up by 0.10%. Thous...

Stockhead’s Top 10 at 10, published at 10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

Local markets follow Wall St ‘hopetimism’ lower Small caps smashed, down circa 3% Pot stock CAU delivers ASX first ever pot stock profit The Benchmark is down 1.95% and the small caps index is down 2.7% after climbing late in the session...

Stockhead’s Top 10 at 10, published at 10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

Adherium (ASX: ADR) has announced that it has received US FDA clearance to market application connecting GSK’s Ellipta inhaler users with its new Hailie sensor with physiological parameters for monitoring Asthma and COPD medication...

US FDA approves the first clinical trial using naturally derived psychedelic drugs It could open possibilities for other clinical trials to follow suit Best and worst biotechs over the past month In a ground-breaking development, the US F...

A recent research reveals which biotech segments VCs are ploughing billions of dollars into We list the ASX companies that are operating within those thematics We also list the best and worst ASX biotech performers over the past week and m...

Respiratory eHealth company Adherium (ADR) signs its first UK distribution deal with Helicon Health to sell the Hailie sensor range and cloud data services Helicon Health is a medical technology company that delivers technological innovati...

Benchmark and small cap index down hard Life on the indices can be hard, unless your in energy, possibly materials Pearl Gull Iron is an island, literally and figuratively   The ASX200 and its emerging companies sidekick have retreated in...

Respiratory eHealth company Adherium (ASX:ADR) has announced the appointment of Tara Creaven-Capasso as its vice president of quality, regulatory and clinical affairs.

Aussie small cap index falls 1.4% The ASX200 down 1.65% Thursday is Arafura Day!   Down less than 2% and I think we can call that a win. No one likes the sight of blood and after the major Wall Street indices shed more than 3.5% a piece,...

XEC down 2.7% XJO down 1.8% Dateline Resources (ASX: DTR) hits the trifecta    Markets across Asia are mostly heading downtown following Wall Street’s latest sell-off.  Tech names are in the biggest mess thanks to the latest inspired chao...

Respiratory eHealth, remote monitoring and data management solutions company Adherium (ASX:ADR) has announced the release of the latest Hailie platform integration tools.

The Healthcare sector has been struggling as the pandemic wanes But most money managers are still bullish on the sector The biggest movements and news from ASX healthcare stocks this week  Dr Anthony Faucci, America’s top infectious disea...

Digital health company Adherium (ASX:ADR) has appointed Francis White as the vice president of global business development based in the UK.

The healthcare sector is experiencing a dry run IPO listings have fallen significantly on weak market appetite  A snapshot of the return of recent ASX Healthcare IPO stocks We are currently in the longest and steepest bear market for biot...

Biotech sector has had a tough time recently But there are signs of things improving this year A look at biotech movers on the ASX in the past fortnight Biotech stocks entered a bear phase in the middle of 2021, and things haven’t improve...

Respiratory eHealth company Adherium (ASX:ADR) has submitted to the US FDA for 510(k) clearance to connect Ellipta inhaler users with its new Hailie sensor.

Telehealth was already a growing space even before the pandemic, but COVID had launched it into the mainstream. At the height of the pandemic in 2020, data from Research and Markets showed that 76% of hospitals in the US were using teleheal...

The ongoing lawsuit involving Johnson & Johnson (J&J)’s talc products took a controversial turn in the courts this week. The healthcare giant is currently staring down 38,000 claims that its talc products (including the famous baby...

The ASX 200 Health Index (XHJ) is falling by 0.3% at the time of writing, compared to the broader index which is down by 0.37%. Visioneering Technologies (ASX:VTI) has enrolled the first patient in its landmark international clinical trial...

Despite closing lower today, the ASX finished 2021 over 13% where it begun. This compares to a loss of just over 1% in 2020 but a gain of over 20% in 2019. But the ASX did retreat today, snapping a winning streak of 6 trading days and all s...

At the time of writing, the ASX XHJ Healthcare index is up 5.55% over the last five trading days, beating the ASX200 benchmark index which was up 2.8% for the period. Here’s a table showing how ASX-listed healthcare stocks have been perform...

It’s been a rocky two weeks for small-cap health companies with 42 gaining ground, 76 losing it, and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. CODE COMPANY PRICE 1 WEEK RETURN %...

Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

It’s been a rocky two weeks for small-cap health companies, with 27 companies gaining ground, 89 losing it and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Name Price % Six Mont...

The ASX finished 0.67% higher, marking the best performance by the Australian bourse since early October. Almost all sectors finished higher with energy and tech – two sectors under siege in recent weeks – recording gains of 2.07% and 1.9%...

It’s been a rocky two weeks for small-cap health companies, with 33 companies gaining ground, 86 losing it and 16 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Company Price % Six M...

Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

The ASX limped into the close on Friday, in a fairly tame finish to a roller-coaster week. Evergrande contagion fears and jitters ahead of the US Fed meeting sparked a sharp selloff on Monday. But a week (or three days) is a long time in ma...

The ASX 200 health stocks index (XHJ) is down by 0.82% at the time of writing, compared to the broader ASX 200 index which is down by 0.08% Respiratory tech specialist, Adherium (ASX:ADR), jumped 12% this morning after saying it was awarded...

Trading Places is Stockhead’s recap of the buys and sells of ASX small cap shares by fund managers and other famous investors over the last fortnight. Specifically, Stockhead tracks substantial shareholder movements, being shareholders hold...

Highlights  ASX 200 ended the trading session on 10 September 2021 in the green zone. Amani Gold, Norwest and Adherium were the top three stocks that traded heavily on ASX. On Friday, 10 September 2021, ASX 200 ended the day’s trad...

The ASX regained some lost ground from yesterday’s bloodbath, but closed this week lower than what it began. The ASX 200 gained 0.5% to close at 7,407 points while the ASX Emerging Companies Index rose 2.45% to close at 2,469. Most sectors...

The Adherium Ltd (ASX: ADR) share price soared to dizzying heights today. This comes after the digital healthcare company announced it has received a 510(k) clearance from the United States Food and Drug Administration (FDA). At the end of...

After treading water since the start of September, the ASX 200 took a dive in Thursday trade to finish 1.90% lower. Stocks lost ground at the opening bell and kept falling throughout the day, with steady falls across the board. Local stocks...

The ASX Health Care index (XHJ) was down by 0.11% this morning, compared with the broader ASX 200 index which fell by more than 1% at the time of writing. Medicinal cannabis company, Epsilon Healthcare (ASX:EPN), jumped by 20% out of the bl...

Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

Respiratory eHealth company Adherium (ASX:ADR) has announced that it has received US FDA) 510(k) clearance to market its next-generation Hailie Sensor with physiological measures for monitoring asthma and COPD medication use....

The ASX 200 rose 0.07%, closing at 7,529 points while the ASX Emerging Companies Index climbed 1.21% to close at 2,461. Energy lost 1.68% and resources lost 1.09% but most other sectors gained with the best being tech which rose 1.15%.   TO...

Although earnings results were the main theme in August, there were also some notable healthcare breakthroughs on the ASX. Dimerix (ASX:DXB) jumped 45% during the month after announcing the commencement of ACTION 3, a Phase III study in pat...

It’s been a mixed two weeks for small-cap health companies, with only 45 companies gaining ground, 76 losing it and 23 flatlining. Rhinomed (ASX:RNO) was the biggest gainer, up a massive 85% for the fortnight after scoring a contract with N...

The ASX 200 health stocks index is tracking the broader index well over the past two weeks. Both the XHJ Health Sector and the ASX 200 benchmark rose by 3% over this period. A handful of ASX health stocks have seen their prices skyrocket du...

It’s been a mixed two weeks for small-cap health companies, with only 38 companies gaining ground, 74 losing it and 21 flatlining. Analytica Limited (ASX:ALT) was the biggest gainer, up 25% from 8 to 20 July, followed by  Rhinomed (ASX:RNO)...

Closing Bell is Stockhead’s daily recap of the ASX’s biggest winners and losers. Data is taken at the market close – at 4.10pm AEDT. Stocks highlighted in yellow rose (or fell) after making announcements during intraday trade. WINNERS Scrol...

It’s been a mixed two weeks for small-cap health companies, with 60 companies gaining ground and 52 losing it – and 21 flatlining. Botanix Pharma Ltd (ASX:BOT) was the biggest gainer, up 38% from 23 June to 7 July, and Suda Pharmaceuticals...

Closing Bell is Stockhead’s daily recap of the ASX’s biggest winners and losers. Data is taken at the market close – at 4.10pm AEDT. Stocks highlighted in yellow rose (or fell) after making announcements during intraday trade.   WINNERS Scr...